Welcome to our dedicated page for Damora Therapeutics SEC filings (Ticker: DMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Damora Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Damora Therapeutics's regulatory disclosures and financial reporting.
BlackRock, Inc. reported a passive ownership stake in Damora Therapeutics Inc. common stock on a Schedule 13G. BlackRock and certain of its business units beneficially own 3,143,576 shares of Damora common stock, representing 5.1 % of the outstanding class as of June 30, 2026.
BlackRock has sole voting power over 3,072,238 shares and sole dispositive power over 3,143,576 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have the right to receive dividends or sale proceeds from these shares, but no individual person holds more than five percent of Damora’s outstanding common stock through these arrangements.
Damora Therapeutics, Inc. completed a redomestication from Delaware to the Cayman Islands effective July 16, 2026, via a Plan of Conversion. The company now exists as a Cayman Islands exempted company while continuing to operate as Damora Therapeutics, Inc. and to be treated as a U.S. corporation for federal tax purposes.
Each outstanding share of Delaware common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Cayman company, and each preferred share converted into the corresponding Cayman preferred share. Options, rights and restricted stock units now relate to the same number of Cayman ordinary shares. Nasdaq trading continues under the symbol DMRA, with a new CUSIP G2646Y104 from the open on July 20, 2026, without trading interruption.
The company’s internal affairs and shareholder rights are now governed by Cayman law and the Cayman Memorandum and Articles of Association, and certain shareholder rights changed as described in the prior proxy statement. Business, management, obligations, assets, liabilities, material contracts, SEC reporting status and accounting treatment are stated to be unaffected. On July 16, 2026, Damora also entered into new indemnification agreements with all directors and executive officers, providing indemnification and advancement of expenses subject to specified terms.
Damora Therapeutics, Inc. General Counsel Winslow Garrett reported routine equity compensation activity involving restricted stock units (RSUs) and a small share sale tied to taxes. On July 3, 2026, 680 RSUs were settled into 680 shares of common stock at a stated price of $0.00 per share as part of their scheduled vesting from a January 3, 2024 award. On the same date, 640 RSUs from this award remained outstanding. On July 6, 2026, 245 shares of common stock were sold at $29.98 per share to cover tax obligations in connection with the RSU vesting under the company’s 2020 Equity Incentive Plan, which the filing describes as a mandated, non-discretionary sale. Following these transactions, Garrett holds 2,289 shares of Damora Therapeutics common stock directly.
DMRA provides a Form 144 notice listing proposed sales of Common Stock. The filing names Maxim Group as broker and lists planned cash sales tied to option exercises dated 01/03/2025 and 10/09/2024. The reported lot sizes include 5,000, 5,787, and 7,213 shares.
The notice specifies Common Stock and shows a trading market of NASDAQ. The filing supplies broker contact information and the dates 06/22/2026 associated with the filing entries.
Damora Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected Michael Landsittel and Cameron Turtle, D.Phil, as Class III directors to serve until the 2029 annual meeting. An advisory vote approved the compensation of the company’s named executive officers, and stockholders indicated a preference to hold this Say-on-Pay vote every year. Stockholders also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. A quorum was present, with 55,009,938 shares represented out of 60,303,212 shares outstanding on the record date.
Damora Therapeutics ownership update: Amendment No. 1 to a Schedule 13G/A reports that Point72-related entities and Steven A. Cohen beneficially hold 1,193,708 shares of Damora Therapeutics common stock, equal to 2.0% of the class as of the close of business on March 31, 2026. The shares are reported as held by an investment fund managed by Point72 Asset Management, L.P., with voting and dispositive power shared among Point72 entities and Mr. Cohen pursuant to an investment management agreement.
Damora Therapeutics amended a Schedule 13G/A to disclose reporting by Jain Global LLC, Jain Holdings LLC, and Robert Jain concerning Common Stock (CUSIP 36322Q206). The filing states the Reporting Persons hold 0.0% of the class and reports $0.00001 par value per share; ownership rows on the cover show zeros for voting and dispositive powers.
The amendment is signed by an authorized signatory and notes a previously filed power of attorney; it is an ownership disclosure for holders of 5% or less.
Damora Therapeutics disclosed that Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 3,783,000 shares of Common Stock, representing 6.27% of the class. The percentage is calculated using March 17, 2026 outstanding shares of 60,303,212. The statement, filed on a Schedule 13G, identifies Avoro as investment adviser holding the shares on behalf of Avoro Life Sciences Fund LLC and names Dr. Aghazadeh as portfolio manager. The filing lists sole voting and dispositive power over the reported 3,783,000 shares and provides business addresses for the reporting persons.
Damora Therapeutics, Inc. reported a larger net loss as it ramps up development of its mutCALR-targeted pipeline and strengthens its balance sheet. For the quarter ended March 31, 2026, net loss was $27.8 million versus $2.5 million a year earlier, driven mainly by a jump in research and development spending.
Research and development expenses rose to $23.8 million, including $17.0 million related to Paragon under the Paragon Option Agreement and $5.0 million of stock-based compensation from the Paramora warrant obligation. General and administrative costs increased to $7.0 million as the company scales its public-company and infrastructure footprint.
Damora ended the quarter with $532.9 million in cash and cash equivalents, boosted by a February 2026 underwritten offering that raised approximately $295.5 million net, and an accumulated deficit of $515.1 million. Management believes current cash resources can fund operations for at least one year. The company is focusing on its mutCALR portfolio (DMR-001, DMR-002, DMR-003) for myeloproliferative neoplasms and has deprioritized further development of GB3226.
Damora Therapeutics, Inc. executive Brian Burkavage, SVP of Finance, reported a stock option position on a Form 3. The option gives him the right to buy common stock at $32.00 per share for 312,535 underlying shares, expiring on December 15, 2035.
According to the footnote, 25% of this option will vest on December 15, 2026, with the remainder vesting in equal monthly installments through December 15, 2029, subject to his continued service with the company.